Several studies have shown that detection of PD-L1 protein on tumour cells before treatment correlates with a positive response to checkpoint inhibitors. However, some patients who seem to be PD ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

A research team has developed a technology to boost cancer treatment effectiveness by removing a protein used by cancer cells ...

A new research paper was published in Oncotarget, Volume 16, on April 24, 2025, titled “PD-L1 and FOXP3 expression in ...

NICE says these patients taking Opdivo who had more PD-L1 (levels of 10% or more ... regardless of whether there tumours express the protein. NICE's decision-making could leave NHS lung ...

A trial testing the combination of the anti-TIGIT antibody tiragolumab and atezolizumab vs atezolizumab in previously untreated programmed cell death ligand 1 (PD-L1)–high locally advanced ...

PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1.

It is a PD-1/IL-2 bispecific antibody fusion protein designed to enhance efficiency ... By simultaneously inhibiting the PD-1/PD-L1 pathway and activating the IL-2 pathway, IBI363 facilitates ...

A new research paper was published in , Volume 16, on April 24, 2025, titled "PD-L1 and FOXP3 expression in high-grade squamous intraepithelial lesions of the anogenital region." ...